EUVIMEDObjevte EUVIMED
Systematische ÜbersichtOpen access · CC BY-NC-ND 4.0

Risk of Hypoglycemia Associated With Concomitant Use of Insulin Secretagogues and ACE Inhibitors in Adults With Type 2 Diabetes: A Systematic Review

Risiko für Hypoglykämie bei gleichzeitiger Anwendung von Insulinsekretagoga und ACE-Hemmern bei Erwachsenen mit Typ-2-Diabetes: systematische Übersichtsarbeit

Patricia Y Chu iD, Emma K Edmondson iD, James H Flory iD, Jing Huang, Sean Hennessy iD

Clinical Pharmacology & Therapeutics · 2025-04 · 117 (4) · 1005-1011

DOI: 10.1002/cpt.3530 ↗

Auf einen Blick

Die Übersichtsarbeit fand keine eindeutige Assoziation zwischen ACE-Hemmern und Insulinsekretagoga mit schwerer Hypoglykämie. Die Autor:innen sehen die Evidenz aus höherwertigen Studien als gegen einen Zusammenhang sprechend.

Fragestellung

Erhöht die gleichzeitige Anwendung von ACE-Hemmern und Insulinsekretagoga bei Erwachsenen mit Typ-2-Diabetes das Risiko einer schweren Hypoglykämie?

Methode

Systematische Übersichtsarbeit; MEDLINE/PubMed und Embase von Beginn bis Juli 2023; Erwachsene mit T2D unter Insulinsekretagoga und ACEI.

Ergebnisse

472 Treffer, 5 eingeschlossene Studien. Wegen Heterogenität keine Metaanalyse. 2 Studien fanden keinen Zusammenhang; 3 zeigten potenzielle Assoziationen, nur 1 war statistisch signifikant.

Einschränkungen

Heterogenität verhinderte eine Metaanalyse; mehrere Studien mit hohem bzw. kritischem Verzerrungsrisiko durch fehlende Anpassung an Nierenfunktion.

Schlussfolgerung der Autor:innen

Die höherwertigen Studien fanden keinen Zusammenhang zwischen der gleichzeitigen Anwendung von Insulinsekretagoga und ACEI und Hypoglykämie.

Kernaussagen

  • 5 Studien erfüllt die Einschlusskriterien
  • Keine Metaanalyse wegen Heterogenität
  • Höherwertige Studien ohne Zusammenhang

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

At a glance

Systematische Übersicht in Clinical Pharmacology & Therapeutics, published online on 2024-12-13. Written by Patricia Y Chu and 4 co-authors. Institution: Division of Pediatric Endocrinology & Diabetes, Department of Pediatrics, Children's Hospital of Philadelphia, Pennsylvania, Philadelphia, USA. Major MEDLINE topics: Diabetes Mellitus, Type 2, Hypoglycemia, Angiotensin-Converting Enzyme Inhibitors, Hypoglycemic Agents. Cited 3 times so far (Crossref); 27 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: NIDDK NIH HHS, NCI NIH HHS, NIGMS NIH HHS.

Auf einen BlickAbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Insulin secretagogues and angiotensin‐converting enzyme inhibitors (ACEIs) are commonly co‐prescribed for patients with type 2 diabetes (T2D). Case reports suggesting that co‐administration of insulin secretagogues with ACEIs is associated with an increased risk of serious hypoglycemia have led to warnings regarding a drug–drug interaction in widely used drug compendia. However, subsequent studies have had inconsistent results. We performed a systematic review to evaluate the evidence that concomitant use of ACEIs and insulin secretagogues increases the risk of serious hypoglycemia. MEDLINE/PubMed and Embase were searched from inception to July 2023 for studies evaluating adults with T2D treated with insulin secretagogues, such as sulfonylureas or meglitinides, and exposed to an ACEI. The primary outcome was serious hypoglycemia. A literature search yielded 472 papers, of which five met the inclusion criteria. The heterogeneity of the studies precluded meta‐analysis. Two studies using multiple methods to address bias found no association between hypoglycemia and concomitant use of ACEI and insulin secretagogues. Three studies found potential associations, but only one was statistically significant; these studies were at serious or critical risk of bias due to potential confounding from lack of adjustment for renal dysfunction. The higher quality studies found no association between the concomitant use of insulin secretagogues with ACEI and hypoglycemia. Drug compendia and electronic health records should consider updating and removing alerts warning of a drug–drug interaction between insulin secretagogues as a class and ACEIs.

Subjects

MeSH terms (MEDLINE)

Diabetes Mellitus, Type 2HypoglycemiaAngiotensin-Converting Enzyme InhibitorsHypoglycemic AgentsInsulinSecretagoguesHumansDrug InteractionsDrug Therapy, CombinationAdultRisk AssessmentRisk FactorsInsulin Secretagogues

Substances

Angiotensin-Converting Enzyme InhibitorsHypoglycemic AgentsInsulinSecretagoguesInsulin Secretagogues

Authors and institutions

  • Division of Pediatric Endocrinology & Diabetes, Department of Pediatrics, Children's Hospital of Philadelphia, Pennsylvania, Philadelphia, USA.
  • Division of Endocrinology, Diabetes & Metabolism, Department of Medicine, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
  • Center for Real-World Effectiveness and Safety of Therapeutics, Center for Clinical Epidemiology and Biostatistics, and Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University…
  • Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
  • Endocrinology Service, Department of Subspecialty Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

ORCID profiles: Patricia Y Chu, Emma K Edmondson, James H Flory, Sean Hennessy

Funding

  • NIDDK NIH HHS
  • NCI NIH HHS
  • NIGMS NIH HHS

Cite

APA

Chu, P. Y., Edmondson, E. K., Flory, J. H., Huang, J., & Hennessy, S. (2025). Risk of Hypoglycemia Associated With Concomitant Use of Insulin Secretagogues and ACE Inhibitors in Adults With Type 2 Diabetes: A Systematic Review. Clinical Pharmacology & Therapeutics, 117(4), 1005-1011. https://doi.org/10.1002/cpt.3530

Vancouver

Chu PY, Edmondson EK, Flory JH, Huang J, Hennessy S. Risk of Hypoglycemia Associated With Concomitant Use of Insulin Secretagogues and ACE Inhibitors in Adults With Type 2 Diabetes: A Systematic Review. Clinical Pharmacology & Therapeutics. 2025;117(4):1005-1011. doi:10.1002/cpt.3530

BibTeX
@article{Chu2025,
  author = {Chu, Patricia Y and Edmondson, Emma K and Flory, James H and Huang, Jing and Hennessy, Sean},
  title = {Risk of Hypoglycemia Associated With Concomitant Use of Insulin Secretagogues and ACE Inhibitors in Adults With Type 2 Diabetes: A Systematic Review},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2025},
  volume = {117},
  number = {4},
  pages = {1005--1011},
  doi = {10.1002/cpt.3530}
}
Start for free →